Bipolar disorder: the California decision map

Licensed prescriber scope

For this page: lithium as first-line, the suicide evidence and its dissenting trial, monitoring requirements and the discontinuation risk

• Check product identity, approval status, route, dose language, contraindication and monitoring boundaries.
• Open the FDA, trial-registry, regulatory, and primary-study records behind prescribing or drug-safety claims.
• Do not convert investigational evidence, off-label use, or a registered protocol into an approval or recommendation.

Approve, correct, or decline.

• Approve this exact revision only if no correction remains unresolved.
• Return corrections required when a claim overreaches, omits a material limit, or could mislead a California reader.
• Decline when the page falls outside your current professional scope or a conflict prevents an independent read.